Reconstitution with Bcr-Abl negative recipient haematopoiesis after allogeneic BMT for CML

被引：0

作者：

Serrano, J ^{[1
]}

Román, J ^{[1
]}

Castillejo, JA ^{[1
]}

Navarro, JA ^{[1
]}

Pascual, A ^{[1
]}

García-Rubio, I ^{[1
]}

Falcón, M ^{[1
]}

Martín, C ^{[1
]}

Sánchez, J ^{[1
]}

Herrera, C ^{[1
]}

Torres, A ^{[1
]}

机构：

[1] Reina Sofia Hosp, Dept Haematol, Cordoba, Spain

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1998年 / 102卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：318 / 318

页数：1

共 50 条

[21] CHARACTERIZATION OF RECIPROCAL BCR-ABL BREAKPOINTS IN CML BY PCR [J].

ZHANG, JG ;

CROSS, NCP ;

MELO, JV ;

GOLDMAN, JM .

EXPERIMENTAL HEMATOLOGY, 1993, 21 (08) :1091-1091

[22] BCR-ABL transcript levels and BCR-ABL/BCR transcript ratios in CML patients with good or bad response to treatment. [J].

Moravcová, J ;

Regner, J ;

Brezinová, J ;

Klamová, H .

BLOOD, 2001, 98 (11) :264B-264B

[23] Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs [J].

Iraci, Nunzio ;

Valli, Emanuele ;

Gherardi, Samuele ;

Soverini, Simona ;

Kalebic, Thea ;

Baccarani, Michele ;

Martinelli, Giovanni ;

Perini, Giovanni .

BLOOD, 2009, 114 (22) :351-351

[24] Bcr-Abl kinase inhibition as the basis of therapy for CML [J].

Druker, BJ ;

Talpaz, M ;

Resta, D ;

Peng, B ;

Buchdunger, E ;

Ford, J ;

Sawyers, CL .

EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) :130-130

[25] Adherence to BCR-ABL Inhibitors: Issues for CML Therapy [J].

Jabbour, Elias ;

Saglio, Giuseppe ;

Radich, Jerald ;

Kantarjian, Hagop .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04) :223-229

[26] Allogeneic transplant for myelofibrosis, CMML and Philadelphia (Ph) chromosome negative/BCR-ABL negative CML (atypical CML): Potential survival advantage with reduced intensity regimens. [J].

Mittal, P ;

Saliba, RM ;

Giralt, SA ;

Shahjahan, M ;

Cohen, AI ;

Karandish, S ;

Champlin, RE ;

De Lima, M .

BLOOD, 2002, 100 (11) :428A-428A

[27] Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia [J].

Ralph B Arlinghaus .

Oncogene, 2002, 21 :8560-8567

[28] DETECTION OF RESIDUAL DISEASE AFTER BMT FOR CML BY AMPLIFICATION OF THE BCR-ABL BREAKPOINT FROM GENOMIC DNA - COMPARISON WITH RT-PCR [J].

ZHANG, JG ;

LIN, F ;

CROSS, NCP ;

GOLDMAN, JM .

BLOOD, 1994, 84 (10) :A496-A496

[29] Association of BCR-ABL mutation testing in patients with CML with likelihood of improvement in subsequent BCR-ABL test results. [J].

Smyth, Carol ;

Bhan, Jason M. ;

Dhaliwal, Ajitpal Singh ;

Sorokina, Tatiana ;

Parikh, Niyati ;

Levitz, Jason S. ;

Radich, Jerald P. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[30] Long-term lymphoid-restricted split chimerism after myeloablative allogeneic BMT for bcr-abl plus ALL [J].

Spyridonidis, A. ;

Bertz, H. ;

Waterhouse, M. ;

Finke, J. .

BONE MARROW TRANSPLANTATION, 2008, 42 (12) :829-831

← 1 2 3 4 5 →